Updating results

588 results

Sort: Relevance | Date

Permacol for treating anal fistulae (MIB105)

Advice on the use of Permacol for treating anal fistulae (fistula) to aid local decision-making

Medtech innovation briefing Published May 2017

L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

Advice on the use of L-Dex U400 for lymphoedema (lymphedema) after breast cancer treatment to aid local decision-making

Medtech innovation briefing Published July 2017

Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)

Advice on the use of Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest to aid local decision-making

Medtech innovation briefing Published July 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)

Advice on the use of the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry to aid local-decision making

Medtech innovation briefing Published July 2017

TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

Advice on the use of the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation to aid local decision-making

Medtech innovation briefing Published March 2016

Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

Advice on the use of the Axxent electronic brachytherapy system for treating early stage breast cancer to aid local decision-making

Medtech innovation briefing Published August 2016

SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

Advice on the use of SIR-Spheres for treating inoperable hepatocellular carcinoma (HCC) (liver cancer) to aid local decision-making

Medtech innovation briefing Published March 2016

CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)

Advice on the use of the CORTRAK 2 Enteral Access System (EAS) for the placement of nasoenteral feeding tube to aid local decision-making

Medtech innovation briefing Published January 2016 Last updated December 2016

EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)

Advice on the use of EarlySense for heart and respiratory monitoring and predicting patient deterioration to aid local decision-making

Medtech innovation briefing Published January 2016

PneuX for preventing ventilator-associated pneumonia in intensive care (MIB45)

Advice on the use of PneuX for preventing ventilator-associated pneumonia in intensive care to aid local decision-making

Medtech innovation briefing Published November 2015

Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)

Advice on the use of the Acoustic CR Neuromodulation system for adults with chronic subjective tonal tinnitus to aid local decision-making

Medtech innovation briefing Published June 2014

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

Evidence summary Published July 2013 Last updated September 2014

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015

Hypersalivation: oral glycopyrronium bromide (ESUOM15)

Summary of the evidence on oral glycopyrronium bromide for treating hypersalivation (sialorrhoea) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

Summary of the evidence on tranexamic acid for significant haemorrhage (bleeding) after trauma (major injury) to inform local NHS planning and decision-making

Evidence summary Published October 2012

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

Summary of the evidence on melatonin for sleep disorders in children and young people with attention deficit hyperactivity disorder (ADHD)..

Evidence summary Published January 2013

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Minocycline (KTT11)

KTT11 Minocycline Options for local implementation Review and, if appropriate, revise

Key therapeutic topic Published January 2015

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Laxatives (KTT1)

KTT1 Laxatives Options for local implementation Review and, if appropriate, revise prescribing

Key therapeutic topic Published January 2015

Chronic urticaria: off-label doses of cetirizine (ESUOM31)

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Scleroderma: oral mycophenolate (ESUOM32)

Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

Evidence summary Published January 2013

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015

C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

Evidence summary Published December 2015

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

Summary of the evidence on oral mycophenolate for systemic lupus erythematosus (SLE) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Digital ulcers: sildenafil (ESUOM42)

Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

Evidence summary Published March 2015

Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

Evidence summary Published October 2014

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...

Evidence summary Published October 2014

Fatigue in multiple sclerosis: modafinil (ESUOM9)

Summary of the evidence on modafinil for treating fatigue in multiple sclerosis (MS) to inform local NHS planning and decision-making

Evidence summary Published April 2013

VitalPAC for assessing vital signs of patients in hospital (MIB79)

Advice on the use of VitalPAC for assessing vital signs of patients in hospital to aid local decision-making

Medtech innovation briefing Published September 2016

ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

Advice on the use of the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation to aid local decision-making

Medtech innovation briefing Published March 2016

MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

Advice on the MiniMed 640G system with SmartGuard for managing blood glucose levels in type 1 diabetes to aid local decision-making

Medtech innovation briefing Published February 2016

Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)

Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

Medtech innovation briefing Published June 2016

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

Summary of the evidence on guanfacine prolonged-release for attention deficit hyperactivity disorder (ADHD) to inform local NHS planning and decision-making

Evidence summary Published March 2016